CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
TipRanks (Fri, 19-Apr 7:31 PM ET)
TD Cowen says sickle cell therapies may get higher CMS payments
Seeking Alpha News (Mon, 15-Apr 4:46 PM ET)
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
Globe Newswire (Wed, 3-Apr 8:00 AM ET)
Globe Newswire (Mon, 1-Apr 8:00 AM ET)
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
Globe Newswire (Wed, 13-Mar 8:30 AM ET)
Globe Newswire (Wed, 21-Feb 7:30 AM ET)
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
Globe Newswire (Thu, 15-Feb 8:30 AM ET)
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
Globe Newswire (Tue, 13-Feb 8:30 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of April 19, 2024, CRSP stock price declined to $55.05 with 1,702,573 million shares trading.
CRSP has a beta of 2.44, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.25 to the broad based SPY ETF.
CRSP has a market cap of $4.67 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $201 million in Revenue and $1.10 earnings per share. This beat revenue expectation by $70 million and exceeded earnings estimates by $1.17.
In the last 3 years, CRSP stock traded as high as $169.76 and as low as $37.55.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, ARKG, VXF, XBI, IBB.
CRSP has underperformed the market in the last year with a price return of +6.0% while the SPY ETF gained +21.2%. CRSP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.7% and -15.4%, respectively, while the SPY returned +4.3% and -3.5%, respectively.
CRSP support price is $54.59 and resistance is $57.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP stock will trade within this expected range on the day.